Clinical trial for Langerhans cell histiocytosis

Langerhans cell histiocytosis, or LCH for short, is a rare disease of the immune system in which certain immune cells are directed against the patient’s own body. The disease can affect various organs. In order to successfully cure affected children and adolescents, the diverse clinical manifestations of LCH require different therapeutic approaches.

Aim of the trial

Due to the complexity of the symptoms of LCH and their consequences, this trial focuses on treatment adapted to the disease characteristics. Patients are divided into different groups based on the organs affected at the time of diagnosis and treated accordingly. During therapy, checks are continuously made to see how patients are responding to the treatment and whether therapy needs to be intensified. In patients with a very severe form of the disease, where the prognosis is particularly unfavourable, the effectiveness of a stem cell transplant is tested. Once the treatment has been completed, all patients are examined for possible relapses and long-term consequences.

Implementing organisation

Swiss Paediatric Oncology Group (SPOG)